HC Wainwright Brokers Lower Earnings Estimates for ALGS

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Analysts at HC Wainwright dropped their Q1 2025 EPS estimates for shares of Aligos Therapeutics in a report issued on Tuesday, March 11th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings of ($2.37) per share for the quarter, down from their previous estimate of ($1.85). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q2 2025 earnings at ($2.35) EPS, Q3 2025 earnings at ($2.62) EPS, Q4 2025 earnings at $5.91 EPS, FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($8.97) EPS, FY2027 earnings at ($9.99) EPS, FY2028 earnings at ($9.24) EPS and FY2029 earnings at ($9.12) EPS.

Aligos Therapeutics Price Performance

Aligos Therapeutics stock opened at $10.81 on Thursday. The firm has a market capitalization of $38.79 million, a PE ratio of -0.81 and a beta of 2.52. The company’s 50-day moving average is $25.48 and its 200-day moving average is $20.46. Aligos Therapeutics has a fifty-two week low of $6.76 and a fifty-two week high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Monday, March 10th. The company reported ($13.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.63) by ($10.45). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The business had revenue of $0.63 million during the quarter, compared to analyst estimates of $0.43 million. During the same quarter in the previous year, the firm posted ($5.50) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. increased its stake in shares of Aligos Therapeutics by 48.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 325,000 shares of the company’s stock worth $12,948,000 after purchasing an additional 106,187 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Aligos Therapeutics during the 4th quarter worth about $2,751,000. Avantax Advisory Services Inc. bought a new stake in shares of Aligos Therapeutics during the 4th quarter worth about $1,218,000. Geode Capital Management LLC boosted its holdings in shares of Aligos Therapeutics by 13.3% during the 4th quarter. Geode Capital Management LLC now owns 27,253 shares of the company’s stock worth $1,086,000 after buying an additional 3,197 shares during the period. Finally, Drive Wealth Management LLC bought a new stake in shares of Aligos Therapeutics during the 4th quarter worth about $916,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).